Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synthetic Blood (SYBD) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Hoffmann who wrote (255)	12/22/1998 2:35:00 PM
From: taylorfife	Respond to of 307

Rick...I was talked into buying this stock at .34. In your opinion, will the price get back to .34 any time soon? Thanks.

To: Rick Hoffmann who wrote (255)	1/4/1999 1:09:00 PM
From: John R Resseger	Respond to of 307

Could be the new people don't want to surf the Ohio River.

To: Rick Hoffmann who wrote (255)	1/19/1999 9:23:00 AM
From: t.gawarecki	Read Replies (1) \| Respond to of 307

New Patents ISSUED Synthetic Blood International Inc. Announces Issuance of Two New Patents Business Wire - January 19, 1999 09:18 KETTERING, Ohio--(BUSINESS WIRE)--Jan. 19, 1999--Synthetic Blood International Inc. (SYBD) announced today that two new U.S. patents protecting the company's proprietary perfluorocarbon blood substitute and liquid ventilation technology have been issued. The patents, titled "Perfluorocarbons for biological gas exchange and method" and "Method of assisting normal breathing in a mammal having a lung disorder," claim the use of new perfluorocarbons with improved biological and gas exchange properties. Also claimed is the novel use of two perfluorocarbons with different vapor pressures to control perfluorocarbon persistence and duration of therapeutic activity. "We are very pleased to be able to add two important, new patents to SYBD's patent portfolio," said Richard Kiral, Ph.D., vice president of product development. "Our perfluorocarbon and biosensor technology platforms are now protected by more than 20 issued, licensed, and pending patents." SYBD is developing Oxycyte(TM), a perfluorocarbon blood substitute emulsion; Fluorovent(TM), a perfluorocarbon liquid ventilation product; and an implanted biosensor for continuous monitoring of blood glucose levels in diabetics. Synthetic Blood International is located in Kettering, Ohio, with West Coast offices based in Newport Beach, Calif. The company's stock is traded on the OTC Electronic Bulletin Board, symbol SYBD. The company's Web site is sybd.com and e-mail address is sybd@siscom.net. CONTACT: Synthetic Blood International Inc. Joan Mahan, 800/809-6054